Sinclair Pharma (XPAR:SPH) ROCE % : -12.42% (As of Jun. 2018)

View and export this data going back to . Start your Free Trial

What is Sinclair Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sinclair Pharma's annualized ROCE % for the quarter that ended in Jun. 2018 was -12.42%.

Sinclair Pharma ROCE % Historical Data

The historical data trend for Sinclair Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma ROCE % Chart

Sinclair Pharma Annual Data

Trend

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Dec17

ROCE %

Get a 7-Day Free Trial

-3.74

-11.41

-0.27

-4.23

-1.10

Sinclair Pharma Semi-Annual Data
	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Jun17	Dec17	Jun18
ROCE %	Get a 7-Day Free Trial															-16.19	-0.08	-6.71	4.16	-12.42

Sinclair Pharma ROCE % Calculation

Sinclair Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2017 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2017 )		(A: Jun. 2015 )		(A: Dec. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2017 )		(A: Jun. 2015 )		(A: Dec. 2017 )
	=	-2.748	/	( ( (396.116 - 64.878)	+	(191.288 - 22.841) )	/ 2 )
	=	-2.748	/	( (331.238	+	168.447)	/ 2 )
	=	-2.748	/	249.8425
	=	-1.10 %

Sinclair Pharma's ROCE % of for the quarter that ended in Jun. 2018 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2018 )		(Q: Dec. 2017 )		(Q: Jun. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2018 )		(Q: Dec. 2017 )		(Q: Jun. 2018 )
	=	-21.274	/	( ( (191.288 - 22.841)	+	(192.081 - 17.833) )	/ 2 )
	=	-21.274	/	( ( 168.447	+	174.248 )	/ 2 )
	=	-21.274	/	171.3475
	=	-12.42 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2018) EBIT data.

Sinclair Pharma (XPAR:SPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sinclair Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Sinclair Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinclair Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sinclairispharma.com

Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.